Phase 3 Completed N=44 Randomized Treatment

Oral Ketorolac for Arthroscopic Rotator Cuff Repair

Rotator cuff tear · Postoperative Pain

Source: ClinicalTrials.gov NCT03967847 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2022

Primary outcomePrimary: Postoperative Visual Analog Scale Scores — 30; 20 score/units on a scale

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

1. The investigators aim to examine the use of IV and oral ketorolac as an adjunctive agent to the standard of care pain protocol for postoperative pain control following arthroscopic rotator cuff repair. 2. The investigators hypothesize that the use of IV and oral ketorolac in addition to the standard of care pain protocol will reduce postoperative opioid consumption following arthroscopic rotator cuff repair.

Outcome Measures

Outcome	Result	p-value
PRIMARY Postoperative Visual Analog Scale Scores	30; 20	—
SECONDARY Number of Participants With Retear of Rotator Cuff Repair	3; 2	—

Eligibility Criteria

Inclusion Criteria

Patients between the ages of 18 and 89 years old, male or female
Patients undergoing primary shoulder arthroscopic rotator cuff repair

Exclusion Criteria

Patients below the age of 18 or above the age of 89
Illiterate or non-English speaking patients
Patients with contraindications to Ketorolac
History of alcohol of drug abuse
Chronic use of analgesic or psychotropic drugs
Known peptic ulcer disease or bleeding diathesis
Renal dysfunction

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03967847). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.